Immuno-checkpoint inhibitors (ICI) are becoming an integral part of advanced cancer
treatment. ICI-induced colitis (ICI-C) is one of the most common adverse events that
is usually treated with steroids, infliximab or vedolizumab. All these agents are
immune-suppressants that are associated with certain risks. We describe here an alternative
treatment for ICI-C without diminishing ICI effect or causing toxicity.
To read this article in full you will need to make a payment
Already an online subscriber? Sign in
This article is being published jointly in Gastroenterology and Inflammatory Bowel Diseases.
© 2018 AGA Institute and the Crohn's & Colitis Foundation. Published by Elsevier Inc. All rights reserved.